secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beam Therapeutics Inc. (BEAM)
CIK:        0001745999
Form:       8-K
Filed at:   2022-08-01T23:59:59+00:00
Accession:  0000950170-22-013559
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA places clinical hold on Beam's BEAM-201 IND for T-ALL/T-LL
--------------------------------------------------------------

- FDA clinical hold on BEAM-201 IND for relapsed/refractory T-cell acute lymphoblastic leukemia/T-cell lymphoblastic lymphoma.
- Beam informed via FDA email on July 29, 2022; IND submitted end of June.
- BEAM-201 is an anti-CD7, multiplex-edited allogeneic CAR-T candidate.
- FDA to provide official clinical hold letter within 30 days; Beam plans updates after discussions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1745999/000095017022013559/0000950170-22-013559-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1745999/000095017022013559/beam-20220801.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-013559

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer